Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.
Fill Out Your Profile to share more about you. Learn more...

Breaking Research News from sources other than Breastcancer.org

Options
19899101103104107

Comments

  • debbew
    debbew Member Posts: 237
    edited April 2022
    Options

    Warmer Climate Tied to Favorable Breast Cancer Outcomes

    Higher environmental temperatures are associated with better outcomes (significant improvements in pCR as well as OS) among patients with stage I-III breast cancer, according to research presented in a poster at the NCCN 2022 Annual Conference.

    https://www.cancertherapyadvisor.com/home/news/con...

  • Lumpie
    Lumpie Member Posts: 1,553
    edited April 2022
    Options

    onmagosh... debbew.... your post made my day. Is this an excuse to spend the winter in a warm climate? (Access to care issues aside) :) I am such a wimp about the cold and by this time of year, I am ready to petition for no more winter! Now I have a therapeutic excuse. Love it!

  • norcals
    norcals Member Posts: 209
    edited April 2022
    Options

    Lumpie, debbew, & moth:

    Thanks for keeping this thread active and informing the community on all the research that's out there. This is such a helpful thread

  • debbew
    debbew Member Posts: 237
    edited April 2022
    Options

    Lumpie, I was quite surprised to see that article, too! I wondered if it had anything to do with vitamin D, but that doesn't seem to be what they are thinking.

    Norcals, thanks for the nod! Lumpie has led the way but I'm always interested to see what all the other posters have uncovered.

  • homemom
    homemom Member Posts: 830
    edited April 2022
    Options

    debbew That's great news! I went through all my treatments, surgery during the hottest Florida months May - September

  • moth
    moth Member Posts: 3,293
    edited April 2022
    Options

    timing of chemo - as in morning or afternoon- may affect outcomes

    "patients who received most treatments after noon required fewer dose reductions and were less likely to stop treatment.

    In addition, recurrence rates were highest among patients who received at least 70% of treatments before noon."

    https://www.cancertherapyadvisor.com/home/news/con...


  • bgross144
    bgross144 Member Posts: 5
    edited April 2022
    Options

    test

  • bgross144
    bgross144 Member Posts: 5
    edited April 2022
    Options

    test

  • debbew
    debbew Member Posts: 237
    edited April 2022
    Options

    Cardamonin shows promise for treating aggressive breast cancer

    Study shows that compound from cardamom spice can kill triple-negative breast cancer cells

    https://www.eurekalert.org/news-releases/947459

  • Lumpie
    Lumpie Member Posts: 1,553
    edited April 2022
    Options

    Hepatic Resection for Breast Cancer–Related Liver Metastases

    Published in Metastatic Breast Cancer

    Journal Scan / Research · April 11, 2022

    • This retrospective study from a single institution described the outcomes of patients undergoing liver resection for breast cancer–related liver metastases and identified any clinicopathological variables associated with recurrence or survival. The findings showed that among 20 patients with breast cancer–associated liver metastases, hepatic resection was associated with a median disease-free survival of 50 months and a 5-year OS of 65%.
    • {A} Few patients may benefit from hepatic resection for breast cancer–related liver metastases and this approach appears to be feasible and safe.
    • CONCLUSIONS: This study has demonstrated that liver resection for breast cancer-related liver metastases is feasible, safe and associated with prolonged disease free and overall survival in selected patients. It is likely that this option will be offered to more patients going forward, however, the difficulty lies in selecting out those who will benefit from liver resection particularly given the increasing number of systemic treatments and local ablative methods available that offer good long-term results.
    {Summary, abstract and full article all appear to be free of charge.}
  • karenfizedbo15
    karenfizedbo15 Member Posts: 719
    edited April 2022
    Options

    Hi All, been a while since the crash and just catching up.
    I've had some progression and my MO is suggesting Vinorelbine as next step. However I can't find ANYTHING positive about this drug…apart from it being effective in a mouse trial ina combo to tackle brain mets. It's old, it doesn't seem to be particularly effective and has been 'relegated' to later stage treatment. Does anyone have anything positive on this drug to share?

  • Lumpie
    Lumpie Member Posts: 1,553
    edited April 2022
    Options

    karenfizedbo15, I am so sorry to hear about your progression and concern over drugs. I have taken Vinorelbine. I was on the Aviator trial and got Group B: Trastuzumab + Vinorelbine + Avelumab. It did not help me and I "progressed" off of it really quickly. Sorry that is probably not very encouraging. It looks to me like the trial is still recruiting (https://clinicaltrials.gov/ct2/show/NCT03414658) so it must be working for some people. You might check out the trial. Looks like you are triple + so IDK if that fits with their recruitment. I don't recall it being particularly hard to tolerate. I do think I lost my hair, but that sort of goes with the territory at this point. Next I was on Kadcyla, as part of the DS-8201 clinical trial (control arm), and it did not work for long for me and had some ugly side effects. Then we irradiated my brain and liver (Cyberknife) and I went on DS-8201/Enhertu. The combo has kept things under control thus far. Sure hope you find some thing that is tolerable and works well for you!

  • karenfizedbo15
    karenfizedbo15 Member Posts: 719
    edited April 2022
    Options

    Thanks Lumpie! I’m ER+ and HER2+. You story seems to be the norm, that I can find. Checked the trial link but it’s showing an error. It is encouraging that you’ve managed to find SOMETHING to keep you stable though!

  • Lumpie
    Lumpie Member Posts: 1,553
    edited April 2022
    Options

    Thanks, karenfizedbo15. In case you or any others readers are searching, the Aviator trial is: ClinicalTrials.gov Identifier: NCT03414658. Yes, anything to keep us stable. Thankfully, lots of people having luck on Enhertu. It has some challenging SE's, but for a lot of people, it works. Good luck!


  • bsandra
    bsandra Member Posts: 1,019
    edited April 2022
    Options

    I see this thread is a bit quieter... let's revive it! Some very good news on TDX-D for her2low (IHC +1/+2): https://www.onclive.com/view/fda-grants-breakthrou...

    Saulius

  • bsandra
    bsandra Member Posts: 1,019
    edited April 2022
    Options

    Interesting in-animal study for cyclophosphamide+CSF1R-inhibitor in mTNBC. Some macrophages inhibition mechanisms... Hope such things come into clinical trials sooner than later: https://scienmag.com/a-promising-combination-thera...

    Saulius

  • homemom
    homemom Member Posts: 830
    edited April 2022
    Options

    With some of these articles, I need Cliff Notes For Dummies, if there is such a thing!Loopy

  • bsandra
    bsandra Member Posts: 1,019
    edited May 2022
    Options

    Dear Homemom, Cliff Notes for Dummies would be useful for me too:)D I also sometimes feel they write these articles only for a few selected people - nothing has changed since times of Socrates:)

    Saulius

  • debbew
    debbew Member Posts: 237
    edited May 2022
    Options

    NUS scientists develop painless way to shrink breast cancer using magnetic fields

    https://www.straitstimes.com/singapore/health/nus-...


  • bsandra
    bsandra Member Posts: 1,019
    edited May 2022
    Options

    The most detailed photograph of a cell inner: https://angstrom3d.com/cst-molecular-landscapes

    Man... how complicated life really is:/

    Saulius

  • bsandra
    bsandra Member Posts: 1,019
    edited May 2022
    Options

    Observing ESMO: extremely interesting results in mTNBC BEGONIA clinical trial: 1st line Durvalumab+Dato_DXd = 74% ORR irrespective of PD-L1 status. Amazing!

    image

  • XfitMama2
    XfitMama2 Member Posts: 18
    edited May 2022
    Options

    I’m wondering if anyone has an article or info on the efficacy of full axillary node removal vs radiation of nodes after a positive frozen section of the Sentinal node in surgery, but specifically for those with tumors over 5cm treated with neoadjuvent chemo. I can’t find info on this subset, most articles talk about small tumors and/or don’t mention neoadjuvent chemo.

    Thanks in advance

  • bsandra
    bsandra Member Posts: 1,019
    edited May 2022
    Options

    Dear xfitmama2, can you highlight your diagnosis/histologies/history as decisions are made depending on them? Standard of care could be easily found in ESMO guidelines but I believe you are familiar with them. The discussion in this sphere (LN removal, Sentinel removal, radiation vs removal, mastectomy/lumpectomy&nod removal) is still going on, you can find come comparison studies but I'd be surprised if you found such a comparison for that exact subset.

    Saulius

  • debbew
    debbew Member Posts: 237
    edited May 2022
    Options

    Researchers reveal a possible biological mechanism connecting breast cancer and type 2 diabetes

    https://www.news-medical.net/news/20220530/Researc...


  • debbew
    debbew Member Posts: 237
    edited May 2022
    Options

    Ultrasound-guided microbubbles boost immunotherapy efficacy

    ...In the preclinical study, the MUSIC strategy demonstrated a complete tumor eradication rate of 60% when administered as monotherapy in breast cancer models...

    https://www.sciencedaily.com/releases/2022/05/2205...


  • debbew
    debbew Member Posts: 237
    edited June 2022
    Options

    Cancer-killing virus injected into human for the first time in new clinical trial

    Previous studies have shown that CF33-hNIS is effective against cell culture and animal models of breast, colorectal, pancreatic, ovarian, and lung cancers. During the Phase 1 clinical trial, researchers will test the safety and tolerability of CF33-hNIS in cancer patients by injecting the virus directly into the blood or the tumor.

    https://www.medicalnewstoday.com/articles/cancer-killing-virus-injected-into-human-for-the-first-time-in-new-clinical-trial

  • debbew
    debbew Member Posts: 237
    edited June 2022
    Options

    'Masked' Cancer Drug Kills Tumors While Sparing Healthy Tissue, Early Results Show

    In breast cancer models, our masked IL-12 resulted in a 90 percent cure rate, while treatment with a commonly used immunotherapy called a checkpoint inhibitor resulted in only a 10 percent cure rate.

    https://www.sciencealert.com/masked-cancer-drug-ki...


  • debbew
    debbew Member Posts: 237
    edited June 2022
    Options

    New Biomarker Classifications May Improve Treatment for High-Risk Breast Cancer Patients

    The researchers, whose findings were recently published online in Cancer Cell, show that by combining predictive biomarkers to create response predicting breast cancer subtypes, these subtypes can then be matched to the most effective modern treatments. The best subtyping schemas incorporate Immune, DNA repair, Luminal, and HER2 phenotypes, Treatment assignment using these response predictive subtypes may improve the efficacy of the treatment and patient outcomes.

    https://www.ucsf.edu/news/2022/06/423061/new-bioma...


  • debbew
    debbew Member Posts: 237
    edited June 2022
    Options

    ASCO: AstraZeneca, Daiichi's Enhertu could transform breast cancer treatment with landmark HER2-low show

    At a median follow-up of 18.4 months, Enhertu extended the median time patients had lived without disease worsening to 9.9 months, versus 5.1 months for patients who got physician's choice of chemotherapy. The drug prolonged patients' lives to a median of 23.4 months, compared with 16.8 months for chemo, according to data presented at a plenary session of the 2022 American Society of Clinical Oncology annual meeting.

    https://www.fiercepharma.com/pharma/asco-astrazene...


  • nkb
    nkb Member Posts: 1,561
    edited June 2022
    Options

    Thanks, Debbrew- interesting articles